Rebecca D. Pentz

Dr. Rebecca D. Pentz

Winship Cancer Institute, Emory School of Medicine, 2004 Ridgewood Dr., Office 301, Atlanta, GA 30322, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2012 in Cancer
Verified
Journal Article
Open access
PDF file
RPRebecca D. Pentz
Rebecca D. Pentz
MWMargaret White
Margaret White
RHR. Donald Harvey
R. Donald Harvey
ZFZachary Luke Farmer
Zachary Luke Farmer
YLYuan Liu
Yuan Liu
FKFadlo R. Khuri
Fadlo R. Khuri
BACKGROUND: Ethical concerns about phase 1 trials persist. Important conceptual advances have been made in understanding concepts used to describe misunderstanding. However, a systematic, empirical evaluation of the frequency of misunderstanding incorporating recent developments is lacking.METHODS: The authors queried 95 participants in phase 1 trials to provide a more sophisticated estimate of the proportion who had therapeutic misconception (TM), defined as misunderstanding the research purpose or how research differs from individualized care, and therapeutic misestimation (TMis), defined as incorrectly estimating the chance of a research trial benefit as >20% or underestimating risk as 0%.RESULTS: Sixty‐five of 95 respondents (68.4%) had TM, which was associated in a multivariate analysis with lower education and family income (P = .008 and P = .001, respectively), but TM was not associated with the vulnerability of having hardly any treatment options. Eighty‐nine of 95 respondents (94%) had TMis, although only 18% reported this was a factual estimate. Although the risks of investigational agents and those exacerbated by research, such as uncertain outcomes, were mentioned (39% and 41% of respondents, respectively), risks novel to research, such as research biopsies, were rarely mentioned (3% of respondents). Although most of these respondents believed that their chance of benefit was greater and that their risk was lower than the population chance (optimists) (54.6%), a substantial minority of respondents (37.6%) were pessimists.CONCLUSIONS: TM continues to be prevalent. Estimates of personal benefit were not usually meant to report facts, it remains unknown whether respondents in the current study had TMis. Although they are not more vulnerable, phase 1 participants need improved understanding of key TM concepts, with attention to risks that are not present in standard of care. Cancer 2012. © 2012 American Cancer Society

29 May 2009 in Cancer
Verified
Journal Article
Open access
PDF file
MLMary Jo Lund
Mary Jo Lund
MEMark T. Eliason
Mark T. Eliason
AHAnn E. Haight
Ann E. Haight
KWKevin C. Ward
Kevin C. Ward
JYJohn L. Young
John L. Young
RPRebecca D. Pentz
Rebecca D. Pentz
BACKGROUND.: During the past 50 years, clinical trials have led to dramatic improvement in pediatric cancer survival. Prior studies have shown that racial/ethnic and age groups have not been enrolled proportionally. Whites, Hispanics, and adolescents are under‐represented and black children are over‐represented. This study identifies the current racial/ethnic/age/sex representation in pediatric (ages birth to 19 years) cancer treatment trials.METHODS.: The authors compared the observed proportions (O) of US children enrolled in Children's Oncology Group (COG) clinical trials from 2000 through 2003 with expected proportions (E), based on Surveillance, Epidemiology, and End Results (SEER) data. The enrollees were subgrouped by race/ethnicity, age, sex, and cancer type (solid or lymphohematopoietic). Chi‐square tests and 95% confidence intervals were used for O versus E comparisons.RESULTS.: Although representation was fairly proportional for each racial/ethnic group, significantly under‐represented solid tumor subgroups were whites (males particularly), adolescents ages 10 to 19 years, and Hispanics aged <10 years. For lymphohematopoietic cancers, significantly under‐represented subgroups were blacks, Hispanics, adolescents ages 10 to 19 years, blacks aged <10 years, Hispanics aged <5 years, white and black males, and black and Hispanic females. The most significantly under‐represented groups were adolescents ages 15 to 19 years for both solid (9.1% O vs 34.3% E) and lymphohematopoietic (11.0% O vs 30.2% E) cancers and Hispanic females with lymphohematopoietic cancers (11.9% O vs 20.5% E). COG enrolled 26.8% of expected cancer cases.CONCLUSIONS.: Although racial/ethnic groups are proportionally represented in COG trials, some specific subgroups including the youngest black and Hispanic children, Hispanic females, and particularly white adolescents ages 15 to 19 years may be under‐represented and may benefit from targeted attention. Cancer 2009. © 2009 American Cancer Society.

1 May 2014 in Pediatrics
Verified
Journal Article
Open access
PDF file
RPRebecca D. Pentz
Rebecca D. Pentz
MAMelissa A. Alderfer
Melissa A. Alderfer
WPWendy Pelletier
Wendy Pelletier
KSKristin Stegenga
Kristin Stegenga
AHAnn E. Haight
Ann E. Haight
PHPamela Hinds
Pamela Hinds
BACKGROUND AND OBJECTIVES: In 2010, the Bioethics Committee of the American Academy of Pediatrics issued recommendations that pediatric hematopoietic stem cell donors should have an independent advocate. Formulating appropriate guidelines is hindered by the lack of prospective empirical evidence from families about the experience of siblings during typing and donation. Our aim was to provide these data. METHODS: Families with a child scheduled to undergo hematopoietic stem cell transplant were recruited. All family members, including children aged 9 to 22 years, were eligible. Qualitative interviews were conducted within 3 time periods: pretransplant, 6 to 8, and 9 to 11 months posttransplant. Quantitative scales assessing decision satisfaction and regret were administered at time 2. RESULTS: Thirty-three families were interviewed. Of the 119 family members, 76% perceived there was no choice in the decision to HLA-type siblings; 77% perceived no choice in sibling donation; 86% had no concerns about typing other than needle sticks; and 64% had no concerns about donation. Common concerns raised were dislike of needle sticks (19%), stress before typing results (14%), and fear of donation (15%). Posttransplantation, 33% of donors wished they had been given more information; 56% of donors stated they benefited from donation. Only 1 donor expressed regret posttransplant. CONCLUSIONS: Most family members did not view sibling typing and donation as a choice, were positive about the experience, and did not express regrets. We recommend education for all siblings before typing, comprehensive education for the donor by a health care provider pretransplant, and systematic donor follow-up after transplantation.

6 January 2019 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
JCJohn W. Cook
John W. Cook
MMMegan K. McGrath
Megan K. McGrath
MDMargie D. Dixon
Margie D. Dixon
JSJeffrey M. Switchenko
Jeffrey M. Switchenko
RHR. Donald Harvey
R. Donald Harvey
RPRebecca D. Pentz
Rebecca D. Pentz
Background: With increasing numbers of oncology biosimilars in the approval pipeline, it is important to investigate oncology clinicians’ understanding of biosimilars and what information they need prior to adoption. Methods: Between January and May 2018, 77 oncology clinicians (52 physicians, 16 pharmacists, and 9 advanced practice providers) completed a survey covering three domains: clinician understanding, prescription preferences, and patient involvement. An in-depth interview was designed based on themes identified in the first 50 surveys: cost, safety and efficacy, patient preference, and disease stage. Participants were chosen to participate in the interview based on outlying responses to survey questions. Results: When asked to define a biosimilar, 74% (57/77) of respondents could not give a satisfactory definition, and 40.3% (31/77) considered a biosimilar the same as a generic drug. The most important factor in biosimilar prescription was safety and efficacy (4.51 out of 5) followed closely by cost differences (4.34 out of 5). A 40% increase (53.2–94.8%) in clinicians’ prescribing likelihood was seen after a biosimilar is designated as interchangeable. Participants in this study were split regarding the importance of shared decision-making with patients [50.7% (39/77) important or extremely important, 39.0% (30/77) somewhat or not at all important]. Clinicians were also split concerning the role that pharmacists should play in the decision to prescribe or substitute biosimilars. Conclusion: Understanding of biosimilars is low, and educational needs are high. The information that clinicians deem important to assess, such as safety, efficacy and cost, will need to be provided before they are comfortable prescribing biosimilars.

21 May 2012 in The Oncologist
Verified
Journal Article
Closed access
RPRebecca D. Pentz
Rebecca D. Pentz
WPWendy Pelletier
Wendy Pelletier
MAMelissa A. Alderfer
Melissa A. Alderfer
KSKristin Stegenga
Kristin Stegenga
DFDiane L. Fairclough
Diane L. Fairclough
PHPamela S. Hinds
Pamela S. Hinds
Learning Objectives: After completing this course, the reader will be able to: When the alternative to medical treatment is likely death, ask parents and children whether they agree to the medical plan rather than suggesting they are sharing in “a decision.”Use the model of shared decision in appropriate settings, that is, those in which a bona fide choice exists. CME This article is available for continuing medical education credit at CME.TheOncologist.com Introduction.: Shared decision-making between health care professionals, patients, parents, and guardians is widely recommended today. However, it is unclear what happens when collaborative language is used by physicians in clinical situations for which patients and parents/guardians believe there is no decision to be made. Methods.: We conducted a qualitative study of decision-making for pediatric allogeneic blood and marrow transplantation by interviewing patients, parents, grandparents, donor siblings, and nondonor children after the decision to proceed to transplant but before the transplantation. Each interview was audio recorded, transcribed, and coded for major themes. Results.: In total, 107 members of 30 families at four sites were interviewed, including 15 patients, 22 mothers, 2 stepmothers, 1 grandmother, 19 fathers, 3 stepfathers, 1 grandfather, 13 sibling donors, and 31 nondonor children (siblings, half-siblings, and cousins). In all, 81% of parents/guardians, 73% of patients, 31% of donors, and 29% of other children reported there was no decision to be made. Almost all (88%) parents/guardians indicated that the physician's recommendation was a large determinant in their agreement to go forward with the transplantation. All parents/guardians reported that “agreeing to a plan” was a better description of what their consent entailed. Conclusions.: To be respectful of patients and parents/guardians, we suggest that “agreeing to a plan” may be a better description for what parents/guardians must consider when the alternative to a transplantation is likely death. In this clinical context, the shared decision-making model with a focus on “a decision to be made” may be misleading.

30 March 2020 in The Oncologist
Verified
Journal Article
Open access
PDF file
ASAndrew G. Shuman
Andrew G. Shuman
RPRebecca D. Pentz
Rebecca D. Pentz
This editorial highlights the ethical challenges facing oncologists and clinical investigators during the global COVID-19 pandemic.